<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2024.1464267</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Immunoproteasome acted as immunotherapy &#x2018;coffee companion&#x2019; in advanced carcinoma therapy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Shi</surname>
<given-names>Shaoyan</given-names>
</name>
<uri xlink:href="https://loop.frontiersin.org/people/2007152"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ou</surname>
<given-names>Xuehai</given-names>
</name>
<uri xlink:href="https://loop.frontiersin.org/people/2518585"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Chao</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wen</surname>
<given-names>Hao</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Jiang</surname>
<given-names>Ke</given-names>
</name>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2779633"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<institution>Department of Hand Surgery, Honghui Hospital, Xi&#x2019;an Jiaotong University</institution>, <addr-line>Xi&#x2019;an, Shaanxi</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Pengpeng Zhang, Nanjing Medical University, China</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Anshi Wu, Capital Medical University, China</p>
<p>Jianbin Bi, The First Hospital of China Medical University, China</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Ke Jiang, <email xlink:href="mailto:jiangke05020615@163.com">jiangke05020615@163.com</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>30</day>
<month>08</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1464267</elocation-id>
<history>
<date date-type="received">
<day>13</day>
<month>07</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>08</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Shi, Ou, Liu, Wen and Jiang</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Shi, Ou, Liu, Wen and Jiang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Immunoproteasome is a specialized form of proteasome which plays a crucial role in antigen processing and presentation, and enhances immune responses against malignant cells. This review explores the role of immunoproteasome in the anti-tumor immune responses, including immune surveillance and modulation of the tumor microenvironment, as well as its potential as a target for cancer immunotherapy. Furthermore, we have also discussed the therapeutic potential of immunoproteasome inhibitors, strategies to enhance antigen presentation and combination therapies. The ongoing trials and case studies in urology, melanoma, lung, colorectal, and breast cancers have also been summarized. Finally, the challenges facing clinical translation of immunoproteasome-targeted therapies, such as toxicity and resistance mechanisms, and the future research directions have been addressed. This review underscores the significance of targeting the immunoproteasome in combination with other immunotherapies for solid tumors and its potential broader applications in other diseases.</p>
</abstract>
<kwd-group>
<kwd>immunoproteasome</kwd>
<kwd>immunotherapy</kwd>
<kwd>solid tumors</kwd>
<kwd>immune</kwd>
<kwd>immune checkpoint inhibitors</kwd>
</kwd-group>
<contract-sponsor id="cn001">Natural Science Foundation of Shaanxi Province<named-content content-type="fundref-id">10.13039/501100007128</named-content>
</contract-sponsor>
<counts>
<fig-count count="3"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="80"/>
<page-count count="9"/>
<word-count count="3957"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Cancer Immunity and Immunotherapy</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>The immunoproteasome is a variant of the standard proteasome with distinct catalytic subunits that degrade ubiquitinylated proteins (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). It is activated in both immune and non-immune cells in response to inflammatory cytokines, especially interferon-gamma (IFN-&#x3b3;), and oxidative stress (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>). Nevertheless, the primary function of the immunoproteasome is to cleave intracellular viral or oncogenic proteins into peptides, which are then displayed by the major histocompatibility complex (MHC) class I molecules for CD8+ T cells (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B5">5</xref>). The immunoproteasome differs from the standard proteasome in terms of both enzymatic activity and subunit composition (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>). The &#x3b2;1, &#x3b2;2, and &#x3b2;5 catalytic subunits of the standard proteasome (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>) are respectively substituted with &#x3b2;1i (LMP2), &#x3b2;2i (MECL-1), and &#x3b2;5i (LMP7) in the immunoproteasome (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B10">10</xref>) (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>). These substitutions alter the proteolytic activity of the immunoproteasome, allowing efficient production of peptides with hydrophobic or basic C-terminal residues, which are preferentially bound by the MHC class I molecules for antigen presentation (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>). Thus, immunoproteasomes boosts the ability of the immune system to recognize and respond to intracellular infections and tumor cells by increasing the efficacy and specificity of peptide generation.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Structure and function of proteasomes <bold>(A)</bold> Constitutive proteasome (cP) vs. Immunoproteasome (iP): The cP includes the subunits &#x3b2;1, &#x3b2;2 and &#x3b2;5, which are respectively substituted with &#x3b2;1i, &#x3b2;2i, and &#x3b2;5i in the iP upon stimulation by pro-inflammatory cytokines such as IFN-&#x3b3;. The iP is naturally present in hematopoietic cells. IFN-&#x3b3; also upregulates the regulatory particle PA28, which can bind to both the cP and iP with equal affinity and enhance their activity. <bold>(B)</bold> Proteasome inhibitors can selectively target iP, or both cP and iP, offering potential immunomodulatory and therapeutic strategies against cancer.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1464267-g001.tif"/>
</fig>
<p>Solid tumors are abnormal masses of tissue that can be benign (non-cancerous) or malignant (cancerous) (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>). Depending on the tissue of origin, solid tumors are broadly classified as carcinomas that originate from epithelial cells (e.g., breast, lung, colorectal cancers), and sarcomas that arise from connective tissues (e.g., bones, muscles). Other specific types include gliomas (brain) and hepatomas (liver) (<xref ref-type="bibr" rid="B15">15</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>). Solid tumors are often detected in the advanced stages, which can render the conventional therapies, such as radiation therapy, chemotherapy and surgery, less effective (<xref ref-type="bibr" rid="B18">18</xref>&#x2013;<xref ref-type="bibr" rid="B20">20</xref>). In addition, solid tumors frequently develop resistance to these therapies, leading to recurrence and metastasis. The presence of immune cells, blood vessels, and the extracellular matrix in the tumor microenvironment (TME) significantly influences tumor progression and treatment resistance. The heterogeneity of solid tumors further complicates treatment, as different regions of the same tumor can respond differently to the same therapeutic modality. These challenges underscore the need for novel approaches, including immunotherapy.</p>
<p>Immunotherapy harnesses the host immune system to recognize and eliminate cancer cells. For instance, checkpoint inhibitors can augment the anti-tumor immune response by reversing the inhibitory signals on the effector T cells. Likewise, immune cells engineered to effectively recognize and eliminate tumor cells (i.e., adoptive cell transfer) and cytokines have also been shown to enhance immune-based clearance of the malignant cells. Furthermore, cancer vaccines can stimulate the immune system to target specific tumor antigens (<xref ref-type="bibr" rid="B21">21</xref>&#x2013;<xref ref-type="bibr" rid="B25">25</xref>). However, tumor cells have developed adaptive mechanisms to escape immune detection, such as decreasing antigen presentation or inducing an immunosuppressive TME. Immunotherapeutic strategies can overcome these challenges by promoting the recognition of tumor-specific antigens. In addition, immunotherapies also offer the potential for long-lasting protection against cancer by establishing immunological memory, as well as a viable alternative for tumors that are resistant to conventional therapy. The therapeutic potential of targeting immune-related pathways has been highlighted by the success of checkpoint inhibitors against melanoma and lung cancer among other malignancies (<xref ref-type="bibr" rid="B26">26</xref>&#x2013;<xref ref-type="bibr" rid="B28">28</xref>).</p>
<p>In this review, we have explored the role of immunoproteasome in anti-tumor immune responses and its potential as a therapeutic target for cancer. We have also discussed the current research, clinical applications, and the challenges associated with targeting the immunoproteasome in solid tumors, and identified areas for future research and clinical development.</p>
</sec>
<sec id="s2">
<label>2</label>
<title>Structure and function of immunoproteasomes</title>
<p>The immunoproteasome differs from the standard proteasome on account of three inducible catalytic subunits. The &#x3b2;1i subunit, also referred to as low molecular weight protein 2 (LMP2), is encoded by a gene located within the MHC class II locus, which emphasizes its significant role in immune function (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B30">30</xref>). Unlike the &#x3b2;1 subunit, LMP2 primarily generates peptides with hydrophobic C-termini, which are preferred by MHC class I molecules. LMP2 is upregulated by inflammatory cytokines, which ensures that the immunoproteasome is optimized for processing antigens during immune responses (<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B32">32</xref>). The &#x3b2;2 subunit of the standard proteasome is replaced with the &#x3b2;2i subunit, also referred to as multi-catalytic endopeptidase complex-like 1 (MECL-1) (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B33">33</xref>). MECL-1 enhances cleavage of substrates after basic residues, which generates a broader range of antigenic peptides suitable for MHC class I presentation. The induction of MECL-1 by pro-inflammatory cytokines is an essential step for the activation of CD8+ T cells and the ensuing adaptive immune response (<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B35">35</xref>). Furthermore, the presence of MECL-1 is essential for maintaining the unique substrate specificity of immunoproteasomes. The &#x3b2;5i subunit, also known as LMP7, is the third inducible catalytic subunit of the immunoproteasome, and promotes the generation of hydrophobic peptides or those with basic C-terminal residues. The gene encoding LMP7 is also located in the MHC region, which underscores its role in immune function. It is induced by IFN-&#x3b3; and other pro-inflammatory cytokines, and is necessary for the effective processing of tumor and viral antigens (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>).</p>
<p>IFN-&#x3b3; is a key effector cytokine involved in the immune responses against viral infections and tumors. Exposure to IFN-&#x3b3; leads to upregulation of immunoproteasome subunits in the immune cells (<xref ref-type="bibr" rid="B38">38</xref>). The tumor necrosis factor-alpha (TNF-&#x3b1;) also contributes to the immunoproteasome induction (<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B40">40</xref>). Both cytokines facilitate the assembly of the &#x3b2;1i, &#x3b2;2i, and &#x3b2;5i subunits into the immunoproteasome during immune responses. Various chaperones are involved in this process to ensure correct incorporation and folding of the subunits (<xref ref-type="bibr" rid="B41">41</xref>&#x2013;<xref ref-type="bibr" rid="B43">43</xref>). This regulated assembly ensures that the immunoproteasome is formed efficiently during times of immune activation, providing a tailored response to pathogenic challenges (<xref ref-type="bibr" rid="B44">44</xref>&#x2013;<xref ref-type="bibr" rid="B46">46</xref>).</p>
<p>The transporter associated with antigen processing (TAP) cleaves proteins into smaller peptides during protein degradation, which are then transported into the endoplasmic reticulum (<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B48">48</xref>). Within the endoplasmic reticulum, these peptides are loaded onto MHC class I molecules. When MHC class I molecules are present on the surface of malignant or infected cells, CD8+ T cells are able to recognize and respond to these antigens (<xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B50">50</xref>).</p>
</sec>
<sec id="s3">
<label>3</label>
<title>Immunoproteasome in tumor immunology</title>
<sec id="s3_1">
<label>3.1</label>
<title>Recognition and elimination of cancer cells</title>
<p>Immune cells have the ability to recognize and eliminate cells that express abnormal or cancer-specific antigens, a phenomenon known as immunosurveillance. The immunoproteasome is pivotal to this process, as it generates a wide repertoire of antigenic peptides that are more likely to be recognized by the effector immune cells. The presentation of these peptides by the MHC class I molecules is crucial for the activation of anti-tumor CD8+ cytotoxic T lymphocytes (CTLs) (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B51">51</xref>). Consequently, the immunoproteasome plays a critical role in the prevention and control of cancer progression by assisting the immune system in detecting and eliminating nascent tumor cells.</p>
<p>Solid tumors have developed several mechanisms to avoid immune detection and clearance, even in the face of effective immune surveillance. For instance, tumor cells can downregulate the expression of MHC class I molecules, which reduces antigen presentation and subsequent recognition by CTLs. Additionally, tumors can create an immunosuppressive microenvironment by secreting factors such as TGF-&#x3b2;, IL-10, and VEGF (<xref ref-type="bibr" rid="B52">52</xref>). Likewise, immune checkpoint molecules like PD-L1 that cause T cell exhaustion by triggering inhibitory signals are also typically upregulated on the tumor cells. Finally, mutations or alterations in the immunoproteasome subunits can lower generation of antigenic peptides, and contribute to immune evasion.</p>
</sec>
<sec id="s3_2">
<label>3.2</label>
<title>Role of immunoproteasome in modulating the microenvironment</title>
<p>Apart from ensuring effective presentation of tumor-associated antigens (TAAs) on the MHC class I molecules and thus promoting activation of CTLs (<xref ref-type="bibr" rid="B53">53</xref>, <xref ref-type="bibr" rid="B54">54</xref>), the immunoproteasome also maintains the balance between immune activation and tolerance, and keeps the immunosuppressive elements of the TME in check (<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B52">52</xref>). It can either promote or inhibit the anti-tumor immune response by modulating the activity of various immune cells and the production of cytokines.</p>
<p>Tumor-infiltrating lymphocytes (TILs) are a subset of immune cells that penetrate the tumor stroma, and are indicative of the immune response against malignant cells. Enhanced antigen processing by the immunoproteasome can boost the responsiveness and cytotoxic function of the TILs against tumor cells (<xref ref-type="bibr" rid="B55">55</xref>, <xref ref-type="bibr" rid="B56">56</xref>), which is vital for sustained anti-tumor immune response within the TME. However, tumors often employ immunosuppressive strategies that can hinder TIL function, such as upregulation of checkpoint molecules and the secretion of immunosuppressive cytokines. Targeting the immunoproteasome within the TME can potentially counteract these strategies, and enhance the infiltration, activation, and cytotoxic function of TILs (<xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B58">58</xref>).</p>
</sec>
<sec id="s3_3">
<label>3.3</label>
<title>Immunoproteasome activity in antigen-presenting cells</title>
<p>Antigen-presenting cells (APCs), including macrophages and dendritic cells (<xref ref-type="bibr" rid="B59">59</xref>, <xref ref-type="bibr" rid="B60">60</xref>), process and present antigens to T cells, thereby initiating and modulating immune responses. The immunoproteasome enhances the production of high-quality antigenic peptides, which results in a wide and robust array of tumor-associated antigens being displayed on the surface of APCs. This, in turn, leads to a more effective activation and expansion of CTLs, promoting a stronger and more targeted antitumor immune response. Additionally, by affecting cytokine production and lowering immunosuppressive factors, the immunoproteasome can modify the tumor microenvironment and improve the immune response against tumors as a whole.</p>
</sec>
</sec>
<sec id="s4">
<label>4</label>
<title>Immunoproteasome as a therapeutic target</title>
<sec id="s4_1">
<label>4.1</label>
<title>Enhancing antigen presentation</title>
<p>Enhancing immunoproteasome activity through cytokines, small molecules, or genetic modifications (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>) can boost the ability of the immune system to recognize and destroy cancer cells (<xref ref-type="bibr" rid="B61">61</xref>). For instance, administration of IFN-&#x3b3; and TNF-&#x3b1;, which are potent inducers of immunoproteasome subunits, have been shown to increase the expression and activity of the immunoproteasome (<xref ref-type="bibr" rid="B62">62</xref>). Furthermore, small molecules that mimic the effects of these cytokines or directly activate signaling pathways involved in immunoproteasome regulation are also under investigation. Finally, genetic engineering methods like CRISPR-Cas9 have been used to increase the expression of immunoproteasome subunits in tumor or immune cells, and enhance antigen processing and presentation (<xref ref-type="bibr" rid="B63">63</xref>&#x2013;<xref ref-type="bibr" rid="B65">65</xref>).</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Schematic overview of immunoproteasome activities in cancer. <bold>(A)</bold> Increasing tumor antigen presentation: Immunoproteasomes degrade tumor-associated antigen (TAA) peptides encoded by mutated or cancer germline genes. The transporter associated with antigen processing (TAP) then delivers these peptides into the endoplasmic reticulum (ER). The TAA peptides are trimmed by the ER-associated aminopeptidase (ERAAP), and loaded on MHC I molecules by a complex of tapasin, calreticulin, and ERP57. The MHC I complex loaded with the TAA peptides migrate to the cell surface for presentation to the CTLs. <bold>(B)</bold> Maintaining protein homeostasis: Immunoproteasomes maintain protein homeostasis and protect cells from proteotoxic stress by degrading non-functional and misfolded proteins. <bold>(C)</bold> Degrading tumor suppressor protein IkBa: Immunoproteasome-mediated degradation of IkBa leads to NF-kB activation and cytokine secretion, which in turn recruits neutrophils and initiates colitis-associated cancers (CAC). <bold>(D)</bold> Promoting T cell differentiation: Immunoproteasomes trigger the differentiation of the pro-inflammatory Th1 and Th17 cells, resulting in increased production of IL-17, IL-22, TNF, and IFN-&#x3b3;.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1464267-g002.tif"/>
</fig>
</sec>
<sec id="s4_2">
<label>4.2</label>
<title>Combination therapies</title>
<p>The combination of immunoproteasome inhibitors with immune checkpoint blockers represents a synergistic approach to cancer treatment. Antibodies targeting checkpoint molecules like PD-1, PD-L1, and CTLA-4 have been shown to enhance T cell-mediated elimination of cancer cells. However, the therapeutic efficacy of checkpoint inhibitors can be limited by the immunosuppressive TME and insufficient antigen presentation. Selective inhibition of the immunoproteasome can relieve the immunosuppression in some solid tumors by enhancing antigen presentation. Preclinical studies using animal models have shown that combining immunoproteasome inhibitors and checkpoint blockers prolonged the survival of tumor-bearing animals through enhanced anti-tumor activity. Furthermore, clinical trials are currently exploring this combination strategy in various cancers to evaluate its safety and therapeutic potential.</p>
<p>Immunoproteasome inhibitors can also augment the efficacy of adoptive cell therapies, such as the CAR-T cell therapy or TCR-engineered T cell therapy, by increasing the availability of target antigens within the TME. Similarly, cancer vaccines, which aim to elicit a strong immune response against tumor-specific antigens, can benefit from immunoproteasome inhibitors due to more effective presentation of vaccine-derived peptides. The activation and proliferation of effector T cells can also be increased by combining immunoproteasome inhibitors and cytokines like IL-2 or IL-15, resulting in a potent anti-tumor response.</p>
</sec>
<sec id="s4_3">
<label>4.3</label>
<title>Case studies of specific solid tumors</title>
<p>Bladder cancer is difficult to treat due to its recurrence and resistance to conventional therapies. Cathro et&#xa0;al. showed that immunoproteasome inhibitors synergistically improved the therapeutic effects of checkpoint blockade in an animal model of bladder carcinoma by increasing antigen presentation and infiltration of CTLs (<xref ref-type="bibr" rid="B66">66</xref>). Furthermore, several clinical trials are investigating the impact of combining immunoproteasome inhibitors with standard treatments, such as Bacillus Calmette-Guerin (BCG) therapy, on the overall immune response and recurrence rates in bladder cancer patients (<xref ref-type="bibr" rid="B67">67</xref>&#x2013;<xref ref-type="bibr" rid="B69">69</xref>).</p>
<p>Bone cancers, including osteosarcoma and Ewing sarcoma, are aggressive malignancies that primarily affect children and young adults, and are difficult to treat due to their ability to evade the immune system. Niewerth et&#xa0;al. showed that immunoproteasome inhibitors sensitized bone cancer cells to immune-mediated destruction in a preclinical model by increasing the repertoire of presented antigens and promoting CTL infiltration. In addition to the direct destruction of tumor cells, this strategy also induced a pro-inflammatory TME with sustained immune surveillance. Current research efforts are focused on combining immunoproteasome-targeted therapies with other immunotherapies, such as CAR-T cell therapy, to achieve more favorable outcomes for bone cancer patients (<xref ref-type="bibr" rid="B70">70</xref>).</p>
<p>The immunoproteasome is also a promising therapeutic target for colorectal cancer (CRC). Studies have shown that upregulating immunoproteasome activity in CRC cells can improve antigen presentation and enhance the efficacy of immunotherapies, such as checkpoint blockade (<xref ref-type="bibr" rid="B11">11</xref>). Additionally, immunoproteasome inhibitors have been shown to reduce the immunosuppressive environment of CRC tumors by modulating cytokine production and inhibiting the function of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) (<xref ref-type="bibr" rid="B64">64</xref>, <xref ref-type="bibr" rid="B71">71</xref>). At present, clinical trials are being conducted to assess the safety and efficacy of combining immunoproteasome-targeted therapies with chemotherapy and immunotherapy (<xref ref-type="bibr" rid="B72">72</xref>).</p>
<p>Due to its aggressive nature and the absence of targeted therapies, breast cancer, particularly triple-negative breast cancer (TNBC), presents significant treatment challenges. The immunoproteasome is a promising therapeutic target in breast cancer (<xref ref-type="bibr" rid="B73">73</xref>, <xref ref-type="bibr" rid="B74">74</xref>). Studies show that immunoproteasome activity is crucial for the effective presentation of breast cancer-associated antigens and the activation of CTLs (<xref ref-type="bibr" rid="B75">75</xref>). Furthermore, immunoproteasome inhibitors have been shown to enhance antigen presentation and promote immune cell infiltration in preclinical models of breast cancer. These findings suggest that targeting the immunoproteasome could be an effective strategy to improve the efficacy of existing immunotherapies, such as checkpoint inhibitors, in breast cancer patients. Furthermore, in order to enhance the overall anti-tumor response and raise survival rates for patients with breast cancer, clinical trials are investigating the combination of immunoproteasome-targeted therapies with traditional treatments like radiation therapy and chemotherapy.</p>
<p>Hepatocellular carcinoma (HCC) is one of the main causes of cancer-related death worldwide. Studies in preclinical models have shown that immuneproteasome inhibitors can increase the presentation of antigenic peptides and foster a pro-inflammatory TME, which can improve the effectiveness of immune checkpoint inhibitors, leading to a more effective activation of CTLs against liver cancer cells (<xref ref-type="bibr" rid="B76">76</xref>, <xref ref-type="bibr" rid="B77">77</xref>). This combination approach has reduced tumor growth and improved survival rates in liver cancer models. Furthermore, immunoproteasome-targeted therapies in combination with other treatments, such as transarterial chemoembolization (TACE) and radiofrequency ablation (RFA), are also being investigated to enhance the overall anti-tumor response and improve clinical outcomes in liver cancer patients (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>).</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Schematic overview of immunoproteasome mechanisms in different cancer types <bold>(A)</bold> Enhancing tumor antigen presentation: The immunoproteasome enhances the presentation of tumor antigens in cancers like acute promyelocytic leukemia, breast cancer, non-small cell lung cancer, renal cell carcinoma, melanoma, and colorectal cancer that is negative for microsatellite instability (MSI). This leads to greater T-cell infiltration and subsequent tumor cell death. <bold>(B)</bold> Shifting proteasome population in solid and hematologic cancers: In solid cancers such as prostate, glioblastoma, and gastric cancer, the proteasome population is shifted towards immunoproteasomes by IFN-&#x3b3; and phosphorylated proline-rich Akt substrate of 40 kDa (PRAS40), which is induced by hyperactivated mTOR complex 1 (mTORC1). Increased oxidative stress boosts immunoproteasome expression in hematologic malignancies, including multiple myeloma (MM), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL). Increased oxidative stress boosts immunoproteasome expression in hematologic malignancies, including multiple myeloma (MM), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL). Increased cancer cell survival is a result of the overexpressed immunoproteasome maintaining protein homeostasis. <bold>(C)</bold> Promoting tumorigenesis in colitis-associated cancer: The immunoproteasome degrades I&#x3ba;B in colitis-associated cancer, promoting the differentiation of T cells into the pro-tumorigenic inflammatory T helper cells.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1464267-g003.tif"/>
</fig>
</sec>
</sec>
<sec id="s5">
<label>5</label>
<title>Clinical applications</title>
<p>Numerous clinical trials are currently investigating the efficacy, safety, and optimal use of immunoproteasome-targeted therapies, both inhibitors and enhancers, against various types of solid tumors. For example, several early-phase trials are evaluating the efficacy of immunoproteasome inhibitors such as ONX 0914 in combination with checkpoint inhibitors like pembrolizumab and nivolumab (<xref ref-type="bibr" rid="B78">78</xref>&#x2013;<xref ref-type="bibr" rid="B80">80</xref>). In addition, preliminary results of some clinical trials show that a combination treatment of immunoproteasome inhibitors and anti-PD-1 antibody achieved better response rates and prolonged progression-free survival in patients with melanoma and lung cancer compared to monotherapy. Similarly, cytokine therapies that upregulate immunoproteasome activity have been shown to enhance the anti-tumor immune response. Therefore, targeting the immunoproteasome can improve the effectiveness of current immunotherapies and offer patients with solid tumors new alternatives. However, further studies are required to validate these results and determine the long-term benefits and safety profiles of these combination therapies.</p>
<p>The identification of reliable biomarkers that can predict patient response is essential for the clinical success of immunoproteasome-targeted therapies. For instance, the expression levels of immunoproteasome subunits (&#x3b2;1i, &#x3b2;2i, and &#x3b2;5i), cytokine profiles, and the presence of particular tumor antigens can predict therapeutic efficacy, as well as help screen patients who will most likely to benefit from these therapies. Furthermore, the immunoproteasome activity in tumor tissues and immune cells can serve as an indicator to guide the selection and optimization of immunoproteasome-targeted personalized therapies as per the unique tumor and immune system characteristics of individual patients. For instance, patients with low baseline immunoproteasome activity may benefit from therapies that upregulate its function. In contrast, those with high activity might respond better to inhibitors that modulate their activity. Thus, personalized treatment strategies can enhance the efficacy and minimize the side effects of immunoproteasome-targeted therapies, leading to more effective and individualized cancer care.</p>
</sec>
<sec id="s6">
<label>6</label>
<title>Challenges and future directions</title>
<p>Immunoproteasome inhibitors can also target the proteasomes in normal cells, resulting in the accumulation of damaged or misfolded proteins, which trigger cellular stress and apoptosis. In fact, several side effects of immunoproteasome inhibitors have been reported in clinical trials, such as fatigue, gastrointestinal issues, and hematological toxicities. Developing inhibitors with greater specificity for cancer cells or optimizing dosing regimens can minimize these adverse effects. Furthermore, cancer cells can develop resistance to immunoproteasome inhibitors through various mechanisms, such as upregulation of compensatory proteolytic pathways, mutation of target subunits, or altered expression of proteasome-related genes, leading to relapse and treatment failure. Therefore, it is crucial to elucidate these mechanisms and develop novel strategies to overcome resistance to immunoproteasome inhibitors, such as combining other therapeutic agents that target complementary pathways or using sequential treatment approaches.</p>
<p>Future research should also focus on identifying novel targets within the immunoproteasome pathway. High-throughput screening and advanced genomic techniques can facilitate the discovery of new subunits or regulatory proteins. Additionally, understanding the complex interactions between the immunoproteasome and other cellular pathways can reveal new therapeutic opportunities. For instance, targeting regulatory proteins that control immunoproteasome assembly and activity could provide alternative strategies for modulating its function. Furthermore, advances in drug delivery systems can significantly enhance the efficacy and safety of immunoproteasome-targeted therapies. Nanotechnology-based delivery systems, such as liposomes, nanoparticles, and micelles, can improve the selective targeting of immunoproteasome inhibitors to tumor cells while sparing normal tissues. These systems can also provide controlled and sustained release of the therapeutic agents, reducing the frequency of administration and improving patient compliance. Finally, developing targeted delivery systems that exploit tumor-specific markers or the unique microenvironment of tumors can enhance the precision and effectiveness of immunoproteasome inhibitors.</p>
<p>Immunoproteasome-targeted therapies also hold promise for hematological malignancies such as multiple myeloma and lymphoma due to the high immunoproteasome activity that is frequently observed in these cancers. Exploring the efficacy of these therapies in a broader range of cancers can uncover new clinical applications and benefit a larger patient population. Furthermore, the development of more tailored and effective treatments requires a greater understanding of the differential expression and activity of immunoproteasomes across various cancer types. There is also evidence of a regulatory role of the immunoproteasome in autoimmune diseases and persistent infections. Thus, blocking immunoproteasome activity in autoimmune diseases could mitigate the aberrant immune responses, and reduce inflammation and tissue damage. For instance, immunoproteasome inhibitors have shown promising results in preclinical models of rheumatoid arthritis and lupus. Similarly, enhancing immunoproteasome activity could boost the immune response against chronic infections by improving antigen presentation and T-cell activation. Future research should explore these novel therapeutic possibilities for autoimmune diseases and chronic infections.</p>
<p>In conclusion, the clinical translation of immunoproteasome-targeted therapies will rely on addressing toxicity and resistance mechanisms and exploring novel targets and delivery systems, in order to optimize the therapeutic potential of the immunoproteasome.</p>
</sec>
<sec id="s7" sec-type="conclusions">
<label>7</label>
<title>Conclusion</title>
<p>The immunoproteasome is a key determinant of the response to cancer immunotherapy as it ensures the activation of anti-tumor CTLs by promoting generation of antigenic peptides and their presentation on MHC class I molecules, which in turn improves identification and elimination of cancer cells. Goven its role in modulating the TME and anti-tumor immune responses, the immunoproteasome has garnered considerable interest as a therapeutic target for cancer treatment. Recent studies have greatly improved our understanding of its structure, function, and regulation. Furthermore, clinical trials have reported promising results of immunoproteasome inhibitors, such as ONX 0914, against melanoma and lung cancer. Immunoproteasome-targeted therapies have also been shown to enhance the efficacy of checkpoint blockade therapy and improve patient outcomes. Additionally, strategies that upregulate immunoproteasome activity are also being explored to boost immune responses against tumors.</p>
<p>Future studies should focus on comprehending the mechanisms underlying immunoproteasome inhibitor resistance and developing strategies to address these challenges. Additionally, identifying reliable biomarkers for predicting patient response to immunoproteasome-targeted therapies will be crucial for personalizing treatment plans and maximizing therapeutic efficacy. Novel drug delivery systems and integrating immunoproteasome-targeted therapies with existing treatment regimens could offer new hope for patients with solid tumors, particularly those who do not respond well to conventional therapies. Tailoring treatments based on immunoproteasome activity and patient-specific biomarkers can enhance the precision and effectiveness of cancer therapy, leading to better patient outcomes and reduced side effects.</p>
<p>In conclusion, immunoproteasome-targeted therapies can enhance immune responses and overcome tumor-induced immunosuppression, resulting in more effective and durable treatment for cancer patients.</p>
</sec>
</body>
<back>
<sec id="s8" sec-type="author-contributions">
<title>Author contributions</title>
<p>SS: Funding acquisition, Resources, Writing &#x2013; original draft. XO: Data curation, Investigation, Writing &#x2013; original draft. CL: Formal analysis, Methodology, Writing &#x2013; original draft. HW: Methodology, Validation, Writing &#x2013; original draft. KJ: Writing &#x2013; original draft.</p>
</sec>
<sec id="s9" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.</p>
</sec>
<sec id="s10" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s11" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Basler</surname> <given-names>M</given-names>
</name>
<name>
<surname>Groettrup</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>On the role of the immunoproteasome in protein homeostasis</article-title>. <source>Cells</source>. (<year>2021</year>) <volume>10</volume>:<fpage>3216</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cells10113216</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Bramasole</surname> <given-names>L</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>K</given-names>
</name>
<name>
<surname>Mourtada</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>DNA sensing via the cGAS/STING pathway activates the immunoproteasome and adaptive T-cell immunity</article-title>. <source>EMBO J</source>. (<year>2023</year>) <volume>42</volume>:<elocation-id>e110597</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.15252/embj.2022110597</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnston-Carey</surname> <given-names>HK</given-names>
</name>
<name>
<surname>Pomatto</surname> <given-names>LC</given-names>
</name>
<name>
<surname>Davies</surname> <given-names>KJ</given-names>
</name>
</person-group>. <article-title>The Immunoproteasome in oxidative stress, aging, and disease</article-title>. <source>Crit Rev Biochem Mol Biol</source>. (<year>2015</year>) <volume>51</volume>:<page-range>268&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3109/10409238.2016.1172554</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Basler</surname> <given-names>M</given-names>
</name>
<name>
<surname>Mundt</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bitzer</surname> <given-names>A</given-names>
</name>
<name>
<surname>Schmidt</surname> <given-names>C</given-names>
</name>
<name>
<surname>Groettrup</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>The immunoproteasome: a novel drug target for autoimmune diseases</article-title>. <source>Clin Exp Rheumatol</source>. (<year>2015</year>) <volume>33</volume>:<page-range>S74&#x2013;9</page-range>.</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>W</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>D</given-names>
</name>
<name>
<surname>Su</surname> <given-names>R</given-names>
</name>
<name>
<surname>Ji</surname> <given-names>M</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>HIV-1 nef interacts with LMP7 to attenuate immunoproteasome formation and major histocompatibility complex class I antigen presentation</article-title>. <source>mBio</source>. (<year>2020</year>) <volume>11</volume>:<page-range>e02221&#x2013;19</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/mBio.02221-19</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van den Eynde</surname> <given-names>BJ</given-names>
</name>
<name>
<surname>Morel</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome</article-title>. <source>Curr Opin Immunol</source>. (<year>2001</year>) <volume>13</volume>:<page-range>147&#x2013;53</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0952-7915(00)00197-7</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Limanaqi</surname> <given-names>F</given-names>
</name>
<name>
<surname>Biagioni</surname> <given-names>F</given-names>
</name>
<name>
<surname>Gaglione</surname> <given-names>A</given-names>
</name>
<name>
<surname>Busceti</surname> <given-names>CL</given-names>
</name>
<name>
<surname>Fornai</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>A sentinel in the crosstalk between the nervous and immune system: the (Immuno)-proteasome</article-title>. <source>Front Immunol</source>. (<year>2019</year>) <volume>10</volume>:<elocation-id>628</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2019.00628</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abi Habib</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lesenfants</surname> <given-names>J</given-names>
</name>
<name>
<surname>Vigneron</surname> <given-names>N</given-names>
</name>
<name>
<surname>Van den Eynde</surname> <given-names>BJ</given-names>
</name>
</person-group>. <article-title>Functional differences between proteasome subtypes</article-title>. <source>Cells</source>. (<year>2022</year>) <volume>11</volume>:<fpage>421</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cells11030421</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname> <given-names>S</given-names>
</name>
<name>
<surname>Park</surname> <given-names>SH</given-names>
</name>
<name>
<surname>Choi</surname> <given-names>WH</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>MJ</given-names>
</name>
</person-group>. <article-title>Evaluation of immunoproteasome-specific proteolytic activity using fluorogenic peptide substrates</article-title>. <source>Immune Netw</source>. (<year>2022</year>) <volume>22</volume>:<elocation-id>e28</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.4110/in.2022.22.e28</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>French</surname> <given-names>T</given-names>
</name>
<name>
<surname>Israel</surname> <given-names>N</given-names>
</name>
<name>
<surname>D&#xfc;sedau</surname> <given-names>HP</given-names>
</name>
<name>
<surname>Tersteegen</surname> <given-names>A</given-names>
</name>
<name>
<surname>Steffen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Cammann</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>The immunoproteasome subunits LMP2, LMP7 and MECL-1 are crucial along the induction of cerebral toxoplasmosis</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<elocation-id>619465</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.619465</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Van der Jeught</surname> <given-names>K</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation</article-title>. <source>J Clin Invest</source>. (<year>2021</year>) <volume>131</volume>:<elocation-id>e146832</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1172/JCI146832</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Canel</surname> <given-names>M</given-names>
</name>
<name>
<surname>S&#x142;awi&#x144;ska</surname> <given-names>AD</given-names>
</name>
<name>
<surname>Lonergan</surname> <given-names>DW</given-names>
</name>
<name>
<surname>Kallor</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Upstill-Goddard</surname> <given-names>R</given-names>
</name>
<name>
<surname>Davidson</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer</article-title>. <source>Gut</source>. (<year>2023</year>) <volume>73</volume>:<page-range>131&#x2013;55</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/gutjnl-2022-327927</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maalej</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Merhi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Inchakalody</surname> <given-names>VP</given-names>
</name>
<name>
<surname>Mestiri</surname> <given-names>S</given-names>
</name>
<name>
<surname>Alam</surname> <given-names>M</given-names>
</name>
<name>
<surname>Maccalli</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances</article-title>. <source>Mol Cancer</source>. (<year>2023</year>) <volume>22</volume>:<fpage>20</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12943-023-01723-z</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baulu</surname> <given-names>E</given-names>
</name>
<name>
<surname>Gardet</surname> <given-names>C</given-names>
</name>
<name>
<surname>Chuvin</surname> <given-names>N</given-names>
</name>
<name>
<surname>Depil</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>TCR-engineered T cell therapy in solid tumors: State of the art and perspectives</article-title>. <source>Sci Adv</source>. (<year>2023</year>) <volume>9</volume>:<elocation-id>eadf3700</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/sciadv.adf3700</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname> <given-names>R</given-names>
</name>
<name>
<surname>Du</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Meng</surname> <given-names>F</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Neoantigen-targeted TCR-T cell therapy for solid tumors: How far from clinical application</article-title>. <source>Cancer Lett</source>. (<year>2022</year>) <volume>546</volume>:<fpage>215840</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.canlet.2022.215840</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>K</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Qi</surname> <given-names>D</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>P</given-names>
</name>
<name>
<surname>Fang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical investigations of CAR-T cell therapy for solid tumors</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>896685</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.896685</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pocaterra</surname> <given-names>A</given-names>
</name>
<name>
<surname>Catucci</surname> <given-names>M</given-names>
</name>
<name>
<surname>Mondino</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Adoptive T cell therapy of solid tumors: time to team up with immunogenic chemo/radiotherapy</article-title>. <source>Curr Opin Immunol</source>. (<year>2022</year>) <volume>74</volume>:<page-range>53&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.coi.2021.10.004</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vlashi</surname> <given-names>E</given-names>
</name>
<name>
<surname>Pajonk</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Cancer stem cells, cancer cell plasticity and radiation therapy</article-title>. <source>Semin Cancer Biol</source>. (<year>2015</year>) <volume>31</volume>:<fpage>28</fpage>&#x2013;<lpage>35</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.semcancer.2014.07.001</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hong</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Salama</surname> <given-names>JK</given-names>
</name>
</person-group>. <article-title>The expanding role of stereotactic body radiation therapy in oligometastatic solid tumors: What do we know and where are we going</article-title>? <source>Cancer Treat Rev</source>. (<year>2017</year>) <volume>52</volume>:<fpage>22</fpage>&#x2013;<lpage>32</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ctrv.2016.11.003</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tinkle</surname> <given-names>CL</given-names>
</name>
<name>
<surname>Singh</surname> <given-names>C</given-names>
</name>
<name>
<surname>Lloyd</surname> <given-names>S</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Pappo</surname> <given-names>AS</given-names>
</name>
<etal/>
</person-group>. <article-title>Stereotactic body radiation therapy for metastatic and recurrent solid tumors in children and young adults</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. (<year>2021</year>) <volume>109</volume>:<page-range>1396&#x2013;405</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ijrobp.2020.11.054</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gibney</surname> <given-names>GT</given-names>
</name>
<name>
<surname>Weiner</surname> <given-names>LM</given-names>
</name>
<name>
<surname>Atkins</surname> <given-names>MB</given-names>
</name>
</person-group>. <article-title>Predictive biomarkers for checkpoint inhibitor-based immunotherapy</article-title>. <source>Lancet Oncol</source>. (<year>2016</year>) <volume>17</volume>:<page-range>e542&#x2013;51</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S1470-2045(16)30406-5</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ribas</surname> <given-names>A</given-names>
</name>
<name>
<surname>Wolchok</surname> <given-names>JD</given-names>
</name>
</person-group>. <article-title>Cancer immunotherapy using checkpoint blockade</article-title>. <source>Science</source>. (<year>2018</year>) <volume>359</volume>:<page-range>1350&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.aar4060</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Restifo</surname> <given-names>NP</given-names>
</name>
<name>
<surname>Dudley</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Rosenberg</surname> <given-names>SA</given-names>
</name>
</person-group>. <article-title>Adoptive immunotherapy for cancer: harnessing the T cell response</article-title>. <source>Nat Rev Immunol</source>. (<year>2012</year>) <volume>12</volume>:<page-range>269&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nri3191</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Propper</surname> <given-names>DJ</given-names>
</name>
<name>
<surname>Balkwill</surname> <given-names>FR</given-names>
</name>
</person-group>. <article-title>Harnessing cytokines and chemokines for cancer therapy</article-title>. <source>Nat Rev Clin Oncol</source>. (<year>2022</year>) <volume>19</volume>:<page-range>237&#x2013;53</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41571-021-00588-9</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Adu-Berchie</surname> <given-names>K</given-names>
</name>
<name>
<surname>Brockman</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Pezone</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>DKY</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Cytokine conjugation to enhance T cell therapy</article-title>. <source>Proc Natl Acad Sci U.S.A</source>. (<year>2023</year>) <volume>120</volume>:<elocation-id>e2213222120</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.2213222120</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ravi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Hellmann</surname> <given-names>MD</given-names>
</name>
<name>
<surname>Arniella</surname> <given-names>MB</given-names>
</name>
<name>
<surname>Holton</surname> <given-names>M</given-names>
</name>
<name>
<surname>Freeman</surname> <given-names>SS</given-names>
</name>
<name>
<surname>Naranbhai</surname> <given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer</article-title>. <source>Nat Genet</source>. (<year>2023</year>) <volume>55</volume>:<page-range>807&#x2013;19</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41588-023-01355-5</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalaora</surname> <given-names>S</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>JS</given-names>
</name>
<name>
<surname>Barnea</surname> <given-names>E</given-names>
</name>
<name>
<surname>Levy</surname> <given-names>R</given-names>
</name>
<name>
<surname>Greenberg</surname> <given-names>P</given-names>
</name>
<name>
<surname>Alon</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma</article-title>. <source>Nat Commun</source>. (<year>2020</year>) <volume>11</volume>:<fpage>896</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41467-020-14639-9</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keshet</surname> <given-names>R</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>JS</given-names>
</name>
<name>
<surname>Adler</surname> <given-names>L</given-names>
</name>
<name>
<surname>Iraqi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ariav</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Lim</surname> <given-names>LQJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Targeting purine synthesis in ASS1-expressing tumors enhances the response to immune checkpoint inhibitors</article-title>. <source>Nat Cancer</source>. (<year>2020</year>) <volume>1</volume>:<fpage>894</fpage>&#x2013;<lpage>908</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s43018-020-0106-7</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname> <given-names>SH</given-names>
</name>
<name>
<surname>Xiang</surname> <given-names>YJ</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Nie</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hou</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Co-inhibition of the immunoproteasome subunits LMP2 and LMP7 ameliorates immune thrombocytopenia</article-title>. <source>Front Immunol</source>. (<year>2020</year>) <volume>11</volume>:<elocation-id>603278</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2020.603278</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Tian</surname> <given-names>M</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>G</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>LMP2-mRNA lipid nanoparticle sensitizes EBV-related tumors to anti-PD-1 therapy by reversing T cell exhaustion</article-title>. <source>J Nanobiotechnology</source>. (<year>2023</year>) <volume>21</volume>:<fpage>324</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12951-023-02069-w</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Li</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Immunoproteasome subunit low molecular mass peptide 2 (LMP2) deficiency ameliorates LPS/A&#x3b2;(1-42)-induced neuroinflammation</article-title>. <source>Mol Neurobiol</source>. (<year>2024</year>) <volume>61</volume>:<fpage>28</fpage>&#x2013;<lpage>41</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s12035-023-03564-9</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Lei</surname> <given-names>H</given-names>
</name>
<name>
<surname>Su</surname> <given-names>H</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Inhibition of immunoproteasome reduces infarction volume and attenuates inflammatory reaction in a rat model of ischemic stroke</article-title>. <source>Cell Death Dis</source>. (<year>2015</year>) <volume>6</volume>:<elocation-id>e1626</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/cddis.2014.586</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Opitz</surname> <given-names>E</given-names>
</name>
<name>
<surname>Koch</surname> <given-names>A</given-names>
</name>
<name>
<surname>Klingel</surname> <given-names>K</given-names>
</name>
<name>
<surname>Schmidt</surname> <given-names>F</given-names>
</name>
<name>
<surname>Prokop</surname> <given-names>S</given-names>
</name>
<name>
<surname>Rahnefeld</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Impairment of immunoproteasome function by &#x3b2;5i/LMP7 subunit deficiency results in severe enterovirus myocarditis</article-title>. <source>PloS Pathog</source>. (<year>2011</year>) <volume>7</volume>:<elocation-id>e1002233</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.ppat.1002233</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caudill</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Jayarapu</surname> <given-names>K</given-names>
</name>
<name>
<surname>Elenich</surname> <given-names>L</given-names>
</name>
<name>
<surname>Monaco</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Colbert</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Griffin</surname> <given-names>TA</given-names>
</name>
</person-group>. <article-title>T cells lacking immunoproteasome subunits MECL-1 and LMP7 hyperproliferate in response to polyclonal mitogens</article-title>. <source>J Immunol</source>. (<year>2006</year>) <volume>176</volume>:<page-range>4075&#x2013;82</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.176.7.4075</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leister</surname> <given-names>H</given-names>
</name>
<name>
<surname>Luu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Staudenraus</surname> <given-names>D</given-names>
</name>
<name>
<surname>Lopez Krol</surname> <given-names>A</given-names>
</name>
<name>
<surname>Mollenkopf</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Sharma</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Pro- and antitumorigenic capacity of immunoproteasomes in shaping the tumor microenvironment</article-title>. <source>Cancer Immunol Res</source>. (<year>2021</year>) <volume>9</volume>:<page-range>682&#x2013;92</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/2326-6066.CIR-20-0492</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Namiki</surname> <given-names>S</given-names>
</name>
<name>
<surname>Nakamura</surname> <given-names>T</given-names>
</name>
<name>
<surname>Oshima</surname> <given-names>S</given-names>
</name>
<name>
<surname>Yamazaki</surname> <given-names>M</given-names>
</name>
<name>
<surname>Sekine</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Tsuchiya</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>IRF-1 mediates upregulation of LMP7 by IFN-gamma and concerted expression of immunosubunits of the proteasome</article-title>. <source>FEBS Lett</source>. (<year>2005</year>) <volume>579</volume>:<page-range>2781&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.febslet.2005.04.012</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fellerhoff</surname> <given-names>B</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Laumbacher</surname> <given-names>B</given-names>
</name>
<name>
<surname>Nerlich</surname> <given-names>AG</given-names>
</name>
<name>
<surname>Weiss</surname> <given-names>EH</given-names>
</name>
<name>
<surname>Glas</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>The LMP7-K allele of the immunoproteasome exhibits reduced transcript stability and predicts high risk of colon cancer</article-title>. <source>Cancer Res</source>. (<year>2011</year>) <volume>71</volume>:<page-range>7145&#x2013;54</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-1883</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rundberg Nilsson</surname> <given-names>AJS</given-names>
</name>
<name>
<surname>Xian</surname> <given-names>H</given-names>
</name>
<name>
<surname>Shalapour</surname> <given-names>S</given-names>
</name>
<name>
<surname>Cammenga</surname> <given-names>J</given-names>
</name>
<name>
<surname>Karin</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>IRF1 regulates self-renewal and stress responsiveness to support hematopoietic stem cell maintenance</article-title>. <source>Sci Adv</source>. (<year>2023</year>) <volume>9</volume>:<elocation-id>eadg5391</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/sciadv.adg5391</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Narayanan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Cai</surname> <given-names>CY</given-names>
</name>
<name>
<surname>Assaraf</surname> <given-names>YG</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>HQ</given-names>
</name>
<name>
<surname>Cui</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance</article-title>. <source>Drug Resist Update</source>. (<year>2020</year>) <volume>48</volume>:<fpage>100663</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.drup.2019.100663</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ettari</surname> <given-names>R</given-names>
</name>
<name>
<surname>Previti</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bitto</surname> <given-names>A</given-names>
</name>
<name>
<surname>Grasso</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zappal&#xe0;</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Immunoproteasome-selective inhibitors: A promising strategy to treat hematologic Malignancies, autoimmune and inflammatory diseases</article-title>. <source>Curr Med Chem</source>. (<year>2016</year>) <volume>23</volume>:<page-range>1217&#x2013;38</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2174/0929867323666160318173706</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Du</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xiao</surname> <given-names>X</given-names>
</name>
<name>
<surname>Dai</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Jiao</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Deficient immunoproteasome assembly drives gain of &#x3b1;-synuclein pathology in Parkinson&#x2019;s disease</article-title>. <source>Redox Biol</source>. (<year>2021</year>) <volume>47</volume>:<fpage>102167</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.redox.2021.102167</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Griffin</surname> <given-names>TA</given-names>
</name>
<name>
<surname>Nandi</surname> <given-names>D</given-names>
</name>
<name>
<surname>Cruz</surname> <given-names>M</given-names>
</name>
<name>
<surname>Fehling</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Kaer</surname> <given-names>LV</given-names>
</name>
<name>
<surname>Monaco</surname> <given-names>JJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits</article-title>. <source>J Exp Med</source>. (<year>1998</year>) <volume>187</volume>:<fpage>97</fpage>&#x2013;<lpage>104</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.187.1.97</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murata</surname> <given-names>S</given-names>
</name>
<name>
<surname>Udono</surname> <given-names>H</given-names>
</name>
<name>
<surname>Tanahashi</surname> <given-names>N</given-names>
</name>
<name>
<surname>Hamada</surname> <given-names>N</given-names>
</name>
<name>
<surname>Watanabe</surname> <given-names>K</given-names>
</name>
<name>
<surname>Adachi</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Immunoproteasome assembly and antigen presentation in mice lacking both PA28alpha and PA28beta</article-title>. <source>EMBO J</source>. (<year>2001</year>) <volume>20</volume>:<page-range>5898&#x2013;907</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/emboj/20.21.5898</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Preckel</surname> <given-names>T</given-names>
</name>
<name>
<surname>Fung-Leung</surname> <given-names>WP</given-names>
</name>
<name>
<surname>Cai</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Vitiello</surname> <given-names>A</given-names>
</name>
<name>
<surname>Salter-Cid</surname> <given-names>L</given-names>
</name>
<name>
<surname>Winqvist</surname> <given-names>O</given-names>
</name>
<etal/>
</person-group>. <article-title>Impaired immunoproteasome assembly and immune responses in PA28-/- mice</article-title>. <source>Science</source>. (<year>1999</year>) <volume>286</volume>:<page-range>2162&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.286.5447.2162</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niewerth</surname> <given-names>D</given-names>
</name>
<name>
<surname>Kaspers</surname> <given-names>GJ</given-names>
</name>
<name>
<surname>Assaraf</surname> <given-names>YG</given-names>
</name>
<name>
<surname>van Meerloo</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kirk</surname> <given-names>CJ</given-names>
</name>
<name>
<surname>Anderl</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Interferon-&#x3b3;-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines</article-title>. <source>J Hematol Oncol</source>. (<year>2014</year>) <volume>7</volume>:<fpage>7</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1756-8722-7-7</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prahalad</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kingsbury</surname> <given-names>DJ</given-names>
</name>
<name>
<surname>Griffin</surname> <given-names>TA</given-names>
</name>
<name>
<surname>Cooper</surname> <given-names>BL</given-names>
</name>
<name>
<surname>Glass</surname> <given-names>DN</given-names>
</name>
<name>
<surname>Maksymowych</surname> <given-names>WP</given-names>
</name>
<etal/>
</person-group>. <article-title>Polymorphism in the MHC-encoded LMP7 gene: association with JRA without functional significance for immunoproteasome assembly</article-title>. <source>J Rheumatol</source>. (<year>2001</year>) <volume>28</volume>:<page-range>2320&#x2013;5</page-range>.</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lautscham</surname> <given-names>G</given-names>
</name>
<name>
<surname>Haigh</surname> <given-names>T</given-names>
</name>
<name>
<surname>Mayrhofer</surname> <given-names>S</given-names>
</name>
<name>
<surname>Taylor</surname> <given-names>G</given-names>
</name>
<name>
<surname>Croom-Carter</surname> <given-names>D</given-names>
</name>
<name>
<surname>Leese</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Identification of a TAP-independent, immunoproteasome-dependent CD8+ T-cell epitope in Epstein-Barr virus latent membrane protein 2</article-title>. <source>J Virol</source>. (<year>2003</year>) <volume>77</volume>:<page-range>2757&#x2013;61</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/JVI.77.4.2757-2761.2003</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montserrat</surname> <given-names>V</given-names>
</name>
<name>
<surname>Galocha</surname> <given-names>B</given-names>
</name>
<name>
<surname>Marcilla</surname> <given-names>M</given-names>
</name>
<name>
<surname>V&#xe1;zquez</surname> <given-names>M</given-names>
</name>
<name>
<surname>L&#xf3;pez de Castro</surname> <given-names>JA</given-names>
</name>
</person-group>. <article-title>HLA-B*2704, an allotype associated with ankylosing spondylitis, is critically dependent on transporter associated with antigen processing and relatively independent of tapasin and immunoproteasome for maturation, surface expression, and T cell recognition: relationship to B*2705 and B*2706</article-title>. <source>J Immunol</source>. (<year>2006</year>) <volume>177</volume>:<page-range>7015&#x2013;23</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.177.10.7015</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Bi</surname> <given-names>T</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Targeted inhibition of the immunoproteasome blocks endothelial MHC class II antigen presentation to CD4(+) T cells in chronic liver injury</article-title>. <source>Int Immunopharmacol</source>. (<year>2022</year>) <volume>107</volume>:<fpage>108639</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.intimp.2022.108639</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inholz</surname> <given-names>K</given-names>
</name>
<name>
<surname>Anderl</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Klawitter</surname> <given-names>M</given-names>
</name>
<name>
<surname>Goebel</surname> <given-names>H</given-names>
</name>
<name>
<surname>Maurits</surname> <given-names>E</given-names>
</name>
<name>
<surname>Kirk</surname> <given-names>CJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Proteasome composition in immune cells implies special immune&#x2010;cell&#x2010;specific immunoproteasome function</article-title>. <source>Eur J Immunol</source>. (<year>2024</year>) <volume>54</volume>:<elocation-id>e2350613</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/eji.202350613</pub-id>
</citation>
</ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schultz</surname> <given-names>ES</given-names>
</name>
<name>
<surname>Chapiro</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lurquin</surname> <given-names>C</given-names>
</name>
<name>
<surname>Claverol</surname> <given-names>S</given-names>
</name>
<name>
<surname>Burlet-Schiltz</surname> <given-names>O</given-names>
</name>
<name>
<surname>Warnier</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome</article-title>. <source>J Exp Med</source>. (<year>2002</year>) <volume>195</volume>:<page-range>391&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.20011974</pub-id>
</citation>
</ref>
<ref id="B52">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koerner</surname> <given-names>J</given-names>
</name>
<name>
<surname>Horvath</surname> <given-names>D</given-names>
</name>
<name>
<surname>Oliveri</surname> <given-names>F</given-names>
</name>
<name>
<surname>Li</surname> <given-names>J</given-names>
</name>
<name>
<surname>Basler</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Suppression of prostate cancer and amelioration of the immunosuppressive tumor microenvironment through selective immunoproteasome inhibition</article-title>. <source>Oncoimmunology</source>. (<year>2023</year>) <volume>12</volume>:<fpage>2156091</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/2162402X.2022.2156091</pub-id>
</citation>
</ref>
<ref id="B53">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Pilato</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kfuri-Rubens</surname> <given-names>R</given-names>
</name>
<name>
<surname>Pruessmann</surname> <given-names>JN</given-names>
</name>
<name>
<surname>Ozga</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Messemaker</surname> <given-names>M</given-names>
</name>
<name>
<surname>Cadilha</surname> <given-names>BL</given-names>
</name>
<etal/>
</person-group>. <article-title>CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment</article-title>. <source>Cell</source>. (<year>2021</year>) <volume>184</volume>:<fpage>4512</fpage>&#x2013;<lpage>4530.e22</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2021.07.015</pub-id>
</citation>
</ref>
<ref id="B54">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname> <given-names>M</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>L</given-names>
</name>
<name>
<surname>Cao</surname> <given-names>G</given-names>
</name>
<name>
<surname>Lei</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>P</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy</article-title>. <source>J Immunother Cancer</source>. (<year>2022</year>) <volume>10</volume>:<elocation-id>e004022corr1</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/jitc-2021-004022</pub-id>
</citation>
</ref>
<ref id="B55">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duong</surname> <given-names>E</given-names>
</name>
<name>
<surname>Fessenden</surname> <given-names>TB</given-names>
</name>
<name>
<surname>Lutz</surname> <given-names>E</given-names>
</name>
<name>
<surname>Dinter</surname> <given-names>T</given-names>
</name>
<name>
<surname>Yim</surname> <given-names>L</given-names>
</name>
<name>
<surname>Blatt</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Type I interferon activates MHC class I-dressed CD11b(+) conventional dendritic cells to promote protective anti-tumor CD8(+) T cell immunity</article-title>. <source>Immunity</source>. (<year>2022</year>) <volume>55</volume>:<fpage>308</fpage>&#x2013;<lpage>323.e9</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2021.10.020</pub-id>
</citation>
</ref>
<ref id="B56">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>DhatChinamoorthy</surname> <given-names>K</given-names>
</name>
<name>
<surname>Colbert</surname> <given-names>JD</given-names>
</name>
<name>
<surname>Rock</surname> <given-names>KL</given-names>
</name>
</person-group>. <article-title>Cancer immune evasion through loss of MHC class I antigen presentation</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<elocation-id>636568</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.636568</pub-id>
</citation>
</ref>
<ref id="B57">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paijens</surname> <given-names>ST</given-names>
</name>
<name>
<surname>Vledder</surname> <given-names>A</given-names>
</name>
<name>
<surname>de Bruyn</surname> <given-names>M</given-names>
</name>
<name>
<surname>Nijman</surname> <given-names>HW</given-names>
</name>
</person-group>. <article-title>Tumor-infiltrating lymphocytes in the immunotherapy era</article-title>. <source>Cell Mol Immunol</source>. (<year>2021</year>) <volume>18</volume>:<page-range>842&#x2013;59</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41423-020-00565-9</pub-id>
</citation>
</ref>
<ref id="B58">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname> <given-names>M</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Malafa</surname> <given-names>M</given-names>
</name>
<name>
<surname>Centeno</surname> <given-names>B</given-names>
</name>
<name>
<surname>Hodul</surname> <given-names>PJ</given-names>
</name>
<name>
<surname>Pimiento</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors</article-title>. <source>J Immunother Cancer</source>. (<year>2016</year>) <volume>4</volume>:<fpage>61</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s40425-016-0164-7</pub-id>
</citation>
</ref>
<ref id="B59">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eleftheriadis</surname> <given-names>T</given-names>
</name>
<name>
<surname>Pissas</surname> <given-names>G</given-names>
</name>
<name>
<surname>Antoniadi</surname> <given-names>G</given-names>
</name>
<name>
<surname>Liakopoulos</surname> <given-names>V</given-names>
</name>
<name>
<surname>Stefanidis</surname> <given-names>I</given-names>
</name>
</person-group>. <article-title>CD8+ T-cell auto-reactivity is dependent on the expression of the immunoproteasome subunit LMP7 in exposed to lipopolysaccharide antigen presenting cells and epithelial target cells</article-title>. <source>Autoimmunity</source>. (<year>2013</year>) <volume>46</volume>:<page-range>439&#x2013;45</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3109/08916934.2013.801460</pub-id>
</citation>
</ref>
<ref id="B60">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abusarah</surname> <given-names>J</given-names>
</name>
<name>
<surname>Khodayarian</surname> <given-names>F</given-names>
</name>
<name>
<surname>El-Hachem</surname> <given-names>N</given-names>
</name>
<name>
<surname>Salame</surname> <given-names>N</given-names>
</name>
<name>
<surname>Olivier</surname> <given-names>M</given-names>
</name>
<name>
<surname>Balood</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Engineering immunoproteasome-expressing mesenchymal stromal cells: A potent cellular vaccine for lymphoma and melanoma in mice</article-title>. <source>Cell Rep Med</source>. (<year>2021</year>) <volume>2</volume>:<fpage>100455</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.xcrm.2021.100455</pub-id>
</citation>
</ref>
<ref id="B61">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Besse</surname> <given-names>A</given-names>
</name>
<name>
<surname>Kraus</surname> <given-names>M</given-names>
</name>
<name>
<surname>Mendez-Lopez</surname> <given-names>M</given-names>
</name>
<name>
<surname>Maurits</surname> <given-names>E</given-names>
</name>
<name>
<surname>Overkleeft</surname> <given-names>HS</given-names>
</name>
<name>
<surname>Driessen</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Immunoproteasome activity in chronic lymphocytic leukemia as a target of the immunoproteasome-selective inhibitors</article-title>. <source>Cells</source>. (<year>2022</year>) <volume>11</volume>:<fpage>838</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cells11050838</pub-id>
</citation>
</ref>
<ref id="B62">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>W</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Expression of immunoproteasome subunits in the brains of Toxoplasma gondii-infected mice</article-title>. <source>Exp Mol Pathol</source>. (<year>2021</year>) <volume>123</volume>:<fpage>104684</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.yexmp.2021.104684</pub-id>
</citation>
</ref>
<ref id="B63">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dimasuay</surname> <given-names>KG</given-names>
</name>
<name>
<surname>Schaunaman</surname> <given-names>N</given-names>
</name>
<name>
<surname>Berg</surname> <given-names>B</given-names>
</name>
<name>
<surname>Cervantes</surname> <given-names>D</given-names>
</name>
<name>
<surname>Kruger</surname> <given-names>E</given-names>
</name>
<name>
<surname>Heppner</surname> <given-names>FL</given-names>
</name>
<etal/>
</person-group>. <article-title>Airway epithelial immunoproteasome subunit LMP7 protects against rhinovirus infection</article-title>. <source>Sci Rep</source>. (<year>2022</year>) <volume>12</volume>:<fpage>14507</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-022-18807-3</pub-id>
</citation>
</ref>
<ref id="B64">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burov</surname> <given-names>A</given-names>
</name>
<name>
<surname>Funikov</surname> <given-names>S</given-names>
</name>
<name>
<surname>Vagapova</surname> <given-names>E</given-names>
</name>
<name>
<surname>Dalina</surname> <given-names>A</given-names>
</name>
<name>
<surname>Rezvykh</surname> <given-names>A</given-names>
</name>
<name>
<surname>Shyrokova</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>A cell-based platform for the investigation of immunoproteasome subunit &#x3b2;5i expression and biology of &#x3b2;5i-containing proteasomes</article-title>. <source>Cells</source>. (<year>2021</year>) <volume>10</volume>(<issue>11</issue>):<fpage>3049</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cells10113049</pub-id>
</citation>
</ref>
<ref id="B65">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ladi</surname> <given-names>E</given-names>
</name>
<name>
<surname>Everett</surname> <given-names>C</given-names>
</name>
<name>
<surname>Stivala</surname> <given-names>CE</given-names>
</name>
<name>
<surname>Daniels</surname> <given-names>BE</given-names>
</name>
<name>
<surname>Durk</surname> <given-names>MR</given-names>
</name>
<name>
<surname>Harris</surname> <given-names>SF</given-names>
</name>
<etal/>
</person-group>. <article-title>Design and evaluation of highly selective human immunoproteasome inhibitors reveal a compensatory process that preserves immune cell viability</article-title>. <source>J Med Chem</source>. (<year>2019</year>) <volume>62</volume>:<page-range>7032&#x2013;41</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b00509</pub-id>
</citation>
</ref>
<ref id="B66">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cathro</surname> <given-names>HP</given-names>
</name>
<name>
<surname>Smolkin</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Theodorescu</surname> <given-names>D</given-names>
</name>
<name>
<surname>Jo</surname> <given-names>VY</given-names>
</name>
<name>
<surname>Ferrone</surname> <given-names>S</given-names>
</name>
<name>
<surname>Frierson</surname> <given-names>HF</given-names> <suffix>Jr</suffix>
</name>
</person-group>. <article-title>Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas</article-title>. <source>Cancer Immunol Immunother</source>. (<year>2010</year>) <volume>59</volume>:<page-range>465&#x2013;72</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00262-009-0765-9</pub-id>
</citation>
</ref>
<ref id="B67">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>P&#xe9;rez-Jacoiste As&#xed;n</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Fern&#xe1;ndez-Ruiz</surname> <given-names>M</given-names>
</name>
<name>
<surname>L&#xf3;pez-Medrano</surname> <given-names>F</given-names>
</name>
<name>
<surname>Lumbreras</surname> <given-names>C</given-names>
</name>
<name>
<surname>Tejido</surname> <given-names>&#xc1;</given-names>
</name>
<name>
<surname>San Juan</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Bacillus Calmette-Gu&#xe9;rin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature</article-title>. <source>Med (Baltimore)</source>. (<year>2014</year>) <volume>93</volume>:<page-range>236&#x2013;54</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/MD.0000000000000119</pub-id>
</citation>
</ref>
<ref id="B68">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname> <given-names>J</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Q</given-names>
</name>
</person-group>. <article-title>Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect</article-title>. <source>BioMed Pharmacother</source>. (<year>2020</year>) <volume>129</volume>:<fpage>110393</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.biopha.2020.110393</pub-id>
</citation>
</ref>
<ref id="B69">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rouanne</surname> <given-names>M</given-names>
</name>
<name>
<surname>Adam</surname> <given-names>J</given-names>
</name>
<name>
<surname>Radulescu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Letourneur</surname> <given-names>D</given-names>
</name>
<name>
<surname>Bredel</surname> <given-names>D</given-names>
</name>
<name>
<surname>Mouraud</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>BCG therapy downregulates HLA-I on Malignant cells to subvert antitumor immune responses in bladder cancer</article-title>. <source>J Clin Invest</source>. (<year>2022</year>) <volume>132</volume>(<issue>12</issue>):<elocation-id>e145666</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1172/JCI145666</pub-id>
</citation>
</ref>
<ref id="B70">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niewerth</surname> <given-names>D</given-names>
</name>
<name>
<surname>Jansen</surname> <given-names>G</given-names>
</name>
<name>
<surname>Assaraf</surname> <given-names>YG</given-names>
</name>
<name>
<surname>Zweegman</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kaspers</surname> <given-names>GJ</given-names>
</name>
<name>
<surname>Cloos</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Molecular basis of resistance to proteasome inhibitors in hematological Malignancies</article-title>. <source>Drug Resist Update</source>. (<year>2015</year>) <volume>18</volume>:<fpage>18</fpage>&#x2013;<lpage>35</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.drup.2014.12.001</pub-id>
</citation>
</ref>
<ref id="B71">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leister</surname> <given-names>H</given-names>
</name>
<name>
<surname>Krause</surname> <given-names>FF</given-names>
</name>
<name>
<surname>Mahdavi</surname> <given-names>R</given-names>
</name>
<name>
<surname>Steinhoff</surname> <given-names>U</given-names>
</name>
<name>
<surname>Visekruna</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>The role of immunoproteasomes in tumor-immune cell interactions in melanoma and colon cancer</article-title>. <source>Arch Immunol Ther Exp (Warsz)</source>. (<year>2022</year>) <volume>70</volume>:<fpage>5</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00005-022-00644-x</pub-id>
</citation>
</ref>
<ref id="B72">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoon</surname> <given-names>JY</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>JY</given-names>
</name>
<name>
<surname>Roehrl</surname> <given-names>MHA</given-names>
</name>
</person-group>. <article-title>An investigation into the prognostic significance of high proteasome PSB7 protein expression in colorectal cancer</article-title>. <source>Front Med (Lausanne)</source>. (<year>2020</year>) <volume>7</volume>:<elocation-id>401</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fmed.2020.00401</pub-id>
</citation>
</ref>
<ref id="B73">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname> <given-names>M</given-names>
</name>
<name>
<surname>Song</surname> <given-names>IH</given-names>
</name>
<name>
<surname>Heo</surname> <given-names>SH</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>YA</given-names>
</name>
<name>
<surname>Park</surname> <given-names>IA</given-names>
</name>
<name>
<surname>Bang</surname> <given-names>WS</given-names>
</name>
<etal/>
</person-group>. <article-title>Expression of immunoproteasome subunit LMP7 in breast cancer and its association with immune-related markers</article-title>. <source>Cancer Res Treat</source>. (<year>2019</year>) <volume>51</volume>:<page-range>80&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4143/crt.2017.500</pub-id>
</citation>
</ref>
<ref id="B74">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geoffroy</surname> <given-names>K</given-names>
</name>
<name>
<surname>Araripe Saraiva</surname> <given-names>B</given-names>
</name>
<name>
<surname>Viens</surname> <given-names>M</given-names>
</name>
<name>
<surname>B&#xe9;land</surname> <given-names>D</given-names>
</name>
<name>
<surname>Bourgeois-Daigneault</surname> <given-names>MC</given-names>
</name>
</person-group>. <article-title>Increased expression of the immunoproteasome subunits PSMB8 and PSMB9 by cancer cells correlate with better outcomes for triple-negative breast cancers</article-title>. <source>Sci Rep</source>. (<year>2023</year>) <volume>13</volume>:<fpage>2129</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-023-28940-2</pub-id>
</citation>
</ref>
<ref id="B75">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Kalimutho</surname> <given-names>M</given-names>
</name>
<name>
<surname>Harten</surname> <given-names>S</given-names>
</name>
<name>
<surname>Nanayakkara</surname> <given-names>DM</given-names>
</name>
<name>
<surname>Khanna</surname> <given-names>KK</given-names>
</name>
<name>
<surname>Ragan</surname> <given-names>MA</given-names>
</name>
</person-group>. <article-title>The metastasis suppressor RARRES3 as an endogenous inhibitor of the immunoproteasome expression in breast cancer cells</article-title>. <source>Sci Rep</source>. (<year>2017</year>) <volume>7</volume>:<fpage>39873</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/srep39873</pub-id>
</citation>
</ref>
<ref id="B76">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>French</surname> <given-names>BA</given-names>
</name>
<name>
<surname>Oliva</surname> <given-names>J</given-names>
</name>
<name>
<surname>Bardag-Gorce</surname> <given-names>F</given-names>
</name>
<name>
<surname>French</surname> <given-names>SW</given-names>
</name>
</person-group>. <article-title>The immunoproteasome in steatohepatitis: its role in Mallory-Denk body formation</article-title>. <source>Exp Mol Pathol</source>. (<year>2011</year>) <volume>90</volume>:<page-range>252&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.yexmp.2011.01.004</pub-id>
</citation>
</ref>
<ref id="B77">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oliva</surname> <given-names>J</given-names>
</name>
<name>
<surname>Bardag-Gorce</surname> <given-names>F</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>A</given-names>
</name>
<name>
<surname>French</surname> <given-names>BA</given-names>
</name>
<name>
<surname>French</surname> <given-names>SW</given-names>
</name>
</person-group>. <article-title>The role of cytokines in UbD promoter regulation and Mallory-Denk body-like aggresomes</article-title>. <source>Exp Mol Pathol</source>. (<year>2010</year>) <volume>89</volume>:<fpage>1</fpage>&#x2013;<lpage>8</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.yexmp.2010.04.001</pub-id>
</citation>
</ref>
<ref id="B78">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Dai</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhong</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>ONX0914 inhibition of immunoproteasome subunit LMP7 ameliorates diabetic cardiomyopathy via restraining endothelial-mesenchymal transition</article-title>. <source>Clin Sci (Lond)</source>. (<year>2023</year>) <volume>137</volume>:<page-range>1297&#x2013;309</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1042/CS20230732</pub-id>
</citation>
</ref>
<ref id="B79">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waad Sadiq</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Brioli</surname> <given-names>A</given-names>
</name>
<name>
<surname>Al-Abdulla</surname> <given-names>R</given-names>
</name>
<name>
<surname>&#xc7;etin</surname> <given-names>G</given-names>
</name>
<name>
<surname>Sch&#xfc;tt</surname> <given-names>J</given-names>
</name>
<name>
<surname>Murua Escobar</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Immunogenic cell death triggered by impaired deubiquitination in multiple myeloma relies on dysregulated type I interferon signaling</article-title>. <source>Front Immunol</source>. (<year>2023</year>) <volume>14</volume>:<elocation-id>982720</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2023.982720</pub-id>
</citation>
</ref>
<ref id="B80">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verbrugge</surname> <given-names>SE</given-names>
</name>
<name>
<surname>Assaraf</surname> <given-names>YG</given-names>
</name>
<name>
<surname>Dijkmans</surname> <given-names>BA</given-names>
</name>
<name>
<surname>Scheffer</surname> <given-names>GL</given-names>
</name>
<name>
<surname>Al</surname> <given-names>M</given-names>
</name>
<name>
<surname>den Uyl</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis</article-title>. <source>J Pharmacol Exp Ther</source>. (<year>2012</year>) <volume>341</volume>:<page-range>174&#x2013;82</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1124/jpet.111.187542</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>